EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU

Core Viewpoint - EDAP TMS SA has secured a €36 million credit facility from the European Investment Bank to support the global expansion of its Focal One Robotic HIFU platform and accelerate the development of new clinical indications for its technology [1][2][3] Group 1: Credit Facility Details - The credit facility consists of three tranches: Tranche A for €11 million at an interest rate of 8%, Tranche B for €12 million at 7%, and Tranche C for €13 million at 6% [8] - The maturity date for each tranche is set at 5 years from the date of disbursement [8] - EDAP plans to draw the first tranche of €11 million in the fourth quarter of 2025 [2] Group 2: Strategic Importance - The financing will enable EDAP to expand the reach of its Focal One Robotic HIFU technology, addressing the growing global demand for non-invasive treatment options for cancer and benign conditions [3][4] - The collaboration with the EIB highlights EDAP's commitment to innovation in urological and gynecological care through advanced robotic HIFU technologies [4] Group 3: Company Background - EDAP TMS is recognized as a leader in robotic energy-based therapies, developing and distributing minimally invasive medical devices using ultrasound technology [7] - The Focal One platform is positioned as a leading prostate focal therapy, with potential applications extending beyond prostate cancer [7]